Elanco (ELAN) Q2 2026 Earnings Call Transcript
Elanco Animal Health (ELAN) reported Q2 2026 revenue of $1.368B, up 8% organic constant currency, and adjusted EBITDA of $288M (+21%). Adjusted EPS was $0.34 (+31%). Management raised 2026 revenue guidance to $5.09B-$5.14B and adjusted EPS to $1.10-$1.16, citing innovation sales led by Zenrelia and Credelio Quattro.
How this was made
The 30-second read
Why it matters
The key tradable items are the raised FY revenue, adjusted EBITDA, and adjusted EPS ranges, plus operational metrics (gross margin improvement, net leverage reduction) and product-specific adoption and supply outlooks.
Market read
Guidance raises the earnings outlook and reinforces the innovation portfolio growth narrative, which can drive re-rating and near-term positioning.
What to watch
The call attributes margin expansion to mix and productivity, but investors may question sustainability if direct-to-consumer spend returns diminish or if Experior comparisons re-accelerate volatility.
Background
Elanco Animal Health held its Q2 2026 earnings call, reporting results and updating full-year and third-quarter guidance.
Ticker impact
Elanco reported Q2 results and raised full-year revenue guidance to $5.09B-$5.14B and adjusted EPS to $1.10-$1.16.
Likely positive near-term bias as guidance raises the earnings bar, but investors may scrutinize supply gating for Befrena and inflation risk.
The article discloses multiple forward-looking numeric guidance updates plus specific drivers (gross margin +80 bps, net leverage 3.1x, innovation revenue target raised), which are direct inputs to valuation and positioning.
Market effects
Animal health peers may see read-across on pet health durability and innovation adoption rates, especially dermatology and parasiticides.
US pet health share gains and clinic penetration metrics could influence sentiment toward US-focused animal health distributors.
International pet health growth and Europe OTC ecto momentum (AdTab) support a broader demand narrative beyond the US.
Counterpoint
Despite raised guidance, inflation remains above historical levels and Befrena demand is gated by supply, which could pressure near-term growth quality.
Key entities
- companyElanco Animal Health Incorporated
Reported Q2 2026 results and raised FY 2026 guidance, citing innovation revenue growth and margin expansion.
- executiveJeffrey Simmons
CEO who discussed durable pet health demand and supply timing for Befrena.
- executiveBob VanHimbergen
CFO who highlighted inflation pressure and guidance drivers tied to Elanco Ascend.
